Press Releases

FDA GRANTS FAST TRACK STATUS TO DNATRIX DRUG DNX-2401 FOR RECURRENT GLIOBLASTOMA

Posted on June 17, 2014

SAN DIEGO, CA. – June 17, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status.. read more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas

Posted on February 24, 2014

Grant to Be Used to Fund Ongoing Clinical Trials for Brain Cancer HOUSTON, TX – February 24, 2014 — DNAtrix Inc., a biotech company focusing on the development of oncolytic.. read more

DNAtrix Has Been Named as One of the “Top Advanced Therapies Projects to Watch” and Will Present at the Therapeutic Area Partnerships

Posted on November 18, 2013

Houston, TX – (BUSINESS WIRE – November 18, 2013) – DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that the lead clinical.. read more

DNAtrix Announces Treatment of First Patient in Study with Recurrent Glioblastoma Using DNX-2401 and Temozolomide

Posted on November 14, 2013

Houston, TX – (BUSINESS WIRE – November 14, 2013) – DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that the first patient.. read more

DnaTrix, Inc. To Present Clinical Study Results For DNX-2401 (DELTA 24-RGD), A Conditionally Replication-Competent Adenovirus

Posted on June 18, 2013

Dr. Frank Tufaro to present first-in-human clinical data demonstrating DNX-2401’s ability to treat patients with malignant brain tumors HOUSTON, TX. – June 18, 2013 – DNAtrix Inc., experts in oncolytic.. read more